NCT02180789View on ClinicalTrials.gov

A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
Interventions
DRUG

Tamsulosin OCAS

oral

Trial Locations (1)

Unknown

Linkou District

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Taiwan, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT02180789 - A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation | Biotech Hunter | Biotech Hunter